Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis: Two-Year Follow-Up of the AGENT-IDE Randomized Clinical Trial.

Circulation·2026
Same author

Variability in Cardiac Stress Test Interpretation: Agreement Between Enrollment Sites and Core Laboratories in the Global ISCHEMIA Trial.

Circulation. Population health and outcomes·2026
Same author

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same author

Comprehensive clinical benefit of CCM in HFrEF patients: a win-ratio analysis of FIX-HF-5C randomized trial.

ESC heart failure·2026
Same author

Lessons Learned from the Feasibility Phase of the REvascularization CHoices Among Under-Represented Groups Evaluation (RECHARGE) Trial Program.

American heart journal·2026
Same author

Universal Pulmonary Resistance-Compliance Relationship: And Why It Matters?

Circulation. Heart failure·2026

相关实验视频

Updated: Jun 16, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

美国心脏协会心脏性冲击注册:设计和实施

David A Morrow1, Mariell Jessup2, William T Abraham3

  • 1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (D.A.M.).

Circulation. Cardiovascular quality and outcomes
|June 18, 2024
PubMed
概括

美国心脏协会 (AHA) 启动了一个注册表,收集有关心脏性休克患者的数据. 这个倡议旨在改善对这种严重心脏病的理解和管理.

关键词:
基准测试 (benchmarking) 是一种比较的方法.心脏发生的冲击是心脏性冲击.心脏病 心脏病 是一种疾病.精准医学是一门精准医学.质量改善 质量改善

更多相关视频

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

相关实验视频

Last Updated: Jun 16, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

科学领域:

  • 心脏病学 心脏病学
  • 临床研究 临床研究
  • 医疗保健服务研究 医疗服务研究

背景情况:

  • 心脏性休克是心脏病的严重并发症,死亡率高.
  • 对于更好地了解和管理心脏性休克,存在着重大未满足的需求.
  • 美国心脏协会已经启动了质量改进注册,以应对这些挑战.

研究的目的:

  • 为美国各地心脏性休克患者建立一个全面的注册表.
  • 了解临床表型,管理模式和结果.
  • 为未来的研究创建一个研究基础设施,并改善患者护理.

主要方法:

  • 电子案例记录表格的合作设计与震惊学术研究联盟的定义保持一致.
  • 连续住院患有心脏性休克的患者的注册,无论病因或严重程度如何.
  • 收集关于诊断,治疗,监测,护理过程,并发症和生存的患者级数据.

主要成果:

  • 该登记处于2022年3月31日开始收集临床记录.
  • 目前,有100个中心参与该注册.
  • 收集的数据将使患者管理和结果的评估成为可能.

结论:

  • 该注册表为医学和研究界提供了一个有价值的资源,包含一致的数据.
  • 它旨在通过共享学习加速科学进步.
  • 最终的目标是改善心脏性休克患者的护理质量和治疗结果.